NHS hospitals join with NVIDIA, using AI to interpret radiology scans

pharmaphorum | May 10, 2019

NHS hospitals join with NVIDIA, using AI to interpret radiology scans
The collaboration is part of King’s London Medical Imaging and AI Centre for Value-Based Healthcare, an ongoing project intended to transform 12 clinical pathways in oncology, cardiology and neurology, as well as improve diagnoses and patient care in the NHS. NVIDIA hopes the work could lead to breakthroughs in classifying stroke and neurological impairments, determining the underlying causes of cancers and recommending the best treatments for patients. King’s is installing NVIDIA systems providing 2-petaflops of graphics card-powered supercomputers for AI research, as part of the first phase of the project. It will also use an NVIDIA toolkit along with its own imaging technologies as well as those from partners such as Kheiron Medical, Mirada and Scan. The toolkit from NVIDIA will consist of libraries for data and image processing, AI model processing, and visualisation. Researchers and engineers from NVIDIA and King’s will also join clinicians from major London hospitals onsite at King’s College Hospital, Guy’s and St Thomas’, and South London and Maudsley.

Spotlight

A heart attack is a condition caused by a blockage of blood flow to your heart muscle. The different ways the blood flow may become blocked in the arteries that supply blood to your heart muscle, and the treatments for a heart attack, are explained.

Related News

Grifols to acquire Montreal-based plasma fractionation facility and two purification facilities for US$460 million

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expand plasma collection and fractionation capacity to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Most importantly, this strategic acquisition will strengthen Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system. For more than three decades, Grifols has been a fractionator of Canadian plasma under contract manufacturing services, providing trusted plasma-derived medicines for Canadian patients and their healthcare providers. Throughout these many years Grifols has gained firsthand knowledge of the Canadian healthcare system. This transaction further demonstrates Grifols' commitment to supporting domestic self-sufficiency and security of plasma-protein-product supply.

Read More

US and UK 'lead push against global patent pool for Covid-19 drugs'

The guardian | May 18, 2020

Ministers and officials from every nation will meet via video link on Monday for the annual world health assembly, which is expected to be dominated by efforts to stop rich countries monopolising drugs and future vaccines against Covid-19. As some countries buy up drugs thought to be useful against the coronavirus, causing global shortages, and the Trump administration does deals with vaccine companies to supply America first, there is dismay among public health experts and campaigners who believe it is vital to pull together to end the pandemic. While the US and China face off, the EU has taken the lead. The leaders of Italy, France, Germany and Norway, together with the European commission and council, called earlier this month for any innovative tools, therapeutics or vaccines to be shared equally and fairly.

Read More

RESEARCH

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Algernon Pharmaceuticals, Charles River Laboratories | February 11, 2021

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 ("N,N-Dimethyltryptamine or DMT") for the Company's stroke clinical research program. Algernon's preclinical study of DMT will be conducted at the Charles River research facility in Finland. Charles River Laboratories, Inc. is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. Algernon recently established a clinical research program for the treatment of stroke zeroed in on DMT, a known psychedelic compound that is part of the tryptamine family. The Company plans to be the principal company globally to seek after DMT for stroke in humans and is planning to begin a clinical trial as soon as conceivable in 2021. The Company's decision to investigate DMT, called "The Spirit Molecule," and move it into human trials for stroke, is based on various independent, positive preclinical studies demonstrating that DMT advances neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration. By pursuing a continuous active microdose, the goal will be to provide patients with the therapeutic benefits of DMT, without having a psychedelic experience. This is an important element when considering treating a patient who has quite recently endured a stroke, wherein medications that cause a hallucinogenic response would cause unwanted confusion and stress. DMT Background N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing impacts similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT happens naturally in many plant species and animals and has been utilized in strict ceremonies as a traditional spiritual medicine by indigenous individuals in the Amazonian basin. DMT can also be synthesized in a laboratory. At higher portions, DMT has a rapid onset, intense psychedelic impacts, and a relatively short duration of action with an estimated half-existence of under fifteen minutes. Like other hallucinogens in the tryptamine family, DMT binds to serotonin receptors to deliver euphoria and psychedelic impacts. Because the impacts of DMT don't last long, it has been alluded to in certain circles as the "businessman's outing". Named the "Spirit Molecule" by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, and Algernon consultant, DMT has been shown to induce neuroplasticity in a number of key preclinical studies DMT is believed to activate pathways involved with forming neuron connections and has been shown in studies to increase the number of dendritic spines on cortical neurons. Dendritic spines form synapses (connections) with other neurons and are a major site of molecular activity in the brain. While Dr. Strassman's Phase 1 bolus intravenous human study identified the sub-hallucinogenic portion of DMT in humans, another preclinical animal study demonstrated this same portion level actually retains the neuroplastic impact seen in higher hallucinogenic dosages. Algernon will be investigating an intravenous sub-hallucinogenic portion of DMT in its research and clinical studies. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Read More

Spotlight

A heart attack is a condition caused by a blockage of blood flow to your heart muscle. The different ways the blood flow may become blocked in the arteries that supply blood to your heart muscle, and the treatments for a heart attack, are explained.